Atrasentan for hormone refractory prostate cancer
Following on from information provided to NICE by the company in May 2018, the appraisal of Atrasentan for hormone refractory prostate cancer [ID390] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 390
- Referral date:
- 01 June 2004
- Topic area
- Cancer, Urogenital
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
- 2nd appraisal committee meeting:
- TBC
Project Team
- Assessment Group / Evidence Review Group:
- TBC
- Communications manager:
- TBC
- Executive Lead:
- TBC
- Project manager:
- TBC
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in May 2018, the appraisal of Atrasentan for hormone refractory prostate cancer [ID390] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 May 2005 | Topic summary published |
| 25 August 2006 | This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme. |
| 8 January 2007 | Topic is suspended as the manufacturer has not applied for EMEA regulatory approval at this time |
For further information on our processes and methods, please see our CHTE processes and methods manual